[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637359":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":12,"id":50,"slug":12,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":12,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":72,"whyStopped":12,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Jinling Hospital, China","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","patients received placebo combined with anti-PD-1 therapy and chemotherapy, without additional sodium propionate intervention.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Sodium propionate","EXPERIMENTAL","on the basis of anti-PD-1 therapy combined with chemotherapy, patients were additionally given oral sodium propionate capsules at a dose of 500 mg per capsule, one capsule twice a week, for a total intervention period of 12 weeks.",[18],"Dietary Supplement: Sodium propionate",[20],{"type":21,"name":14,"description":16,"armGroupLabels":22,"otherNames":23},"DIETARY_SUPPLEMENT",[14],[24],"Propionic acid",[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Xinying Wang, MD","CONTACT","+86 13913028866","wangxinying@nju.edu.cn",[32],{"facility":33,"status":12,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Xinying Wang","Nanjing","Jiangsu","210002","China",{"type":39,"coordinates":40},"Point",[41,42],118.77778,32.06167,{"lat":42,"lon":41},[45],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Wang Xinying","prof","100637359",false,"NCT07615907","A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer","Sodium Propionate Combined With Anti-PD-1 Immunotherapy on Tumor Efficacy in Gastric Cancer Patients","PAPGC","Inclusion Criteria:\n\n* Subjects voluntarily participated in the trial and signed the informed consent form;\n* Aged ≥ 18 years and \\\u003C 80 years, regardless of gender;\n* Stable vital signs;\n* Patients with gastric adenocarcinoma confirmed by gastroscopic biopsy;\n* Tumors judged as unresectable by attending physicians;\n* Receiving anti-PD-1 therapy combined with chemotherapy as first-line treatment;\n* No history of allergic diseases and non-allergic constitution;\n* No history of drug abuse;\n* Non-pregnant and non-lactating females (applicable to male subjects as well);\n* No participation in any drug clinical trial (including investigational drugs of this trial) within 3 months prior to enrollment.\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria, or individuals deemed inappropriate for trial participation by investigators;\n* Concurrent primary malignant tumors at other sites;\n* Poor general condition, severe infection, respiratory insufficiency, or other conditions leading to inability to cooperate with the trial;\n* Patients with mental disorders, consciousness disturbance, or poor treatment compliance;\n* Suspected or confirmed history of drug abuse;\n* Immunodeficiency, or long-term use of immunosuppressants and glucocorticoids;\n* Pregnant or lactating women;\n* Sponsors, investigators directly involved in this trial, and their immediate family members;\n* Individuals unsuitable for enrollment for any reason as judged by the investigator.","ALL","18 Years","80 Years",{"count":61,"type":62},20,"ESTIMATED","INTERVENTIONAL",[65],"NA","Eligible patients were randomized into two groups: the sodium propionate group and the control group. In the control group, patients received placebo combined with anti-PD-1 therapy plus chemotherapy without additional sodium propionate intervention. In the sodium propionate group, on the basis of anti-PD-1 therapy combined with chemotherapy, patients were additionally administered oral sodium propionate capsules at a dose of 500 mg (1 capsule) twice weekly, with a total intervention duration of 12 weeks. The primary and secondary outcome indicators will be collected for subsequent analysis.",[68],"Gastric Cancer (GC)",[70,14,71],"Gastric cancer","Immunotherapy","NOT_YET_RECRUITING","2026-05-25",{"date":75,"type":76},"2026-05-29","ACTUAL",{"date":78,"type":62},"2026-05-30",{"date":80,"type":62},"2027-08-30",{"name":5,"class":6},1]